Work

484P Multi-platform characterization of HER2 expression in triple-negative breast cancer

Year: 2023

Type: article

Study design: Observational Study

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.09.660

Authors: A.C. Garrido-Castro, J. Gomez Tejeda Zanudo, J. Navarro, E.T. Richardson, A. Frangieh, A.M. Barkell, A. Mohammed-Abreu, M.E. Hughes, B. Binboga Kurt, T.A. King, E.A. Mittendorf, D. Carroll, S.M. Tolaney, E.C. De Bruin, N.U. Lin

Institutions: Dana-Farber Cancer Institute, Brigham and Women's Hospital, AstraZeneca (United Kingdom), Dana-Farber Brigham Cancer Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Cancer Research Institute, Russian Academy of Sciences

OpenAlex ID: W4387808261

FWCI:

Cites:

Cited by:

Related to: 10